Login to Your Account

Financings NEWS

Despite freer-flowing capital for biotech, Foresite Capital closed its third and largest fund at $450 million, and "our strategy hasn't changed," Christine Aylward, managing director, told BioWorld Today.

The robust health care sector along with an investor passion for immuno-oncology helped Nantkwest Inc. to its $207 million IPO, selling 8.3 million shares at $25 each, above the targeted $20 to $23 price range and 1.3 million more shares than planned.

Biosimilars developer Oncobiologics Inc. has landed a $31 million financing to support continued expansion and development of its platform and pipeline, which includes clinical-stage biosimilars of HumiraAvastin and nine other preclinical candidates poised to take on off-patent biologics.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: